AI주식인사이트AI Stock Insight
C

HLB생명과학

067630KOSDAQ

51.0 / 100

Reference Date: 2026-10-23

Financial Score16.5 / 40
News Sentiment12.5 / 25
Momentum12.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 34.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Life Science operates four business divisions: Medicare, Biotech Development, Medical Device, and Energy, focusing on medical device manufacturing, pharmaceutical R&D, disposable syringe production, and solar EPC projects. Key clients include Abbott and Roche, and the company expanded its medical device market through the 2023 merger with Hwa Jin Medical and acquisition of Tinyco, which specializes in medical-grade nickel-titanium alloys.

Number of Employees

180people

Average Salary

48.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
1.44Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE
-28.70Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
20.67Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼25.5% (2-year basis)

Operating Profit Growth Rate
2.0 / 3

Avg ▲5.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -9.8% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (53%)

Current 3,505Won52-week high 5,15052-week low 1,640
1-month return6.0Point

1m +34.81% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral기업설명회(IR)개최2026-10-12